Locations:
Search IconSearch
December 10, 2017/Cancer/Research

Predictors of 30-day Unplanned Readmissions in Patients with Hematologic Malignancies

Disease-related, clinical and discharge-associated factors

mukherjee_650x450

Patients with hematologic malignancies (HM) are at risk of recurrent 30-day unplanned readmissions (UR), given high symptom burdens and repeated courses of chemotherapy. A team of Cleveland Clinic researchers, led by Sudipto Mukherjee, MD, PhD, MPH, recently sought to identify predictors of recurrent 30-day UR in patients with HM as a first step toward designing interventions for this group. Girish Kunapareddy, MD, MBA, a fellow at Cleveland Clinic Cancer Center, was first author on the abstract.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The study included 259 30-day UR involving 157 hematologic malignancy patients treated at Cleveland Clinic between 2012 and 2015. Hematologic malignancies included in the analysis were acute leukemias, myelodysplastic syndromes and aggressive lymphomas. The tables below show disease-related, clinical and discharge-associated factors that are associated with 30-day UR and independently predictive of subsequent 30-day UR.

”We found several predictors of recurrent 30-day UR, notably gastrointestinal symptoms, prior admission for febrile neutropenia, those with relapsed refractory disease and constitutional symptoms, among others,” says Dr. Mukherjee, associate staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center. “These data shed light on potential areas that can be targeted for interventions to reduce these UR, which are a significant burden on these patients and not an optimal use of medical resources.” For instance, the subset of patients with relapsed/refractory disease may particularly benefit from a specialized program that includes individualized symptom management from a coordinated team and closer ambulatory follow-ups. As part of efforts to reduce 30-day UR, Cleveland Clinic has instituted five-day follow-up for all cancer patients discharged after hospitalization.

Photo Credit: ©Russell Lee

Advertisement

Related Articles

Hands after RT
January 30, 2026/Cancer/Radiation Oncology
Patient Case Study: Radiation Therapy Used to Treat Dupuytren's Disease

Radiation therapy helped shrink hand nodules and improve functionality

Dr. Ali and patient
January 29, 2026/Cancer/News & Insight
Real-World Data Reveals Gap Between Guidelines and Practice in HER2+ Breast Cancer Care

Standard of care is linked to better outcomes, but disease recurrence and other risk factors often drive alternative approaches

Dr. Thomas Budd
January 28, 2026/Cancer/Innovations
Breast Cancer Vaccine Moves One Step Forward

Phase 1 study demonstrates immune response in three quarters of patients with triple-negative breast cancer

Dr. Mukhejee and colleagues
January 22, 2026/Cancer/News & Insight
Rare Cancers and Blood Disease Program Accelerates Diagnostic Journey

Multidisciplinary teams bring pathological and clinical expertise

genetic test
January 16, 2026/Cancer/News & Insight
Five Percent of U.S. Population Carries Pathogenic Variants Associated with Cancer Risk

Genetic variants exist irrespective of family history or other contributing factors

GLP-1
January 12, 2026/Cancer/Blood Cancers
GLP-1a Therapy Improves Survival in Patients with Polycythemia Vera and Myelodysplastic Syndromes

Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Ad